Differentiation of Reprogrammed Mouse Cardiac Fibroblasts into Functional Cardiomyocytes
0301 basic medicine
SOXB1 Transcription Factors
Induced Pluripotent Stem Cells
Kruppel-Like Transcription Factors
Cell Differentiation
Fibroblasts
Cellular Reprogramming
Coculture Techniques
Mice, Inbred C57BL
Proto-Oncogene Proteins c-myc
Kruppel-Like Factor 4
Mice
03 medical and health sciences
Animals
Myocytes, Cardiac
Octamer Transcription Factor-3
Cells, Cultured
Embryoid Bodies
DOI:
10.1007/s12013-012-9487-2
Publication Date:
2012-12-04T17:55:58Z
AUTHORS (8)
ABSTRACT
Fibroblasts can be reprogrammed by ectopic expression of reprogramming factors to yield induced pluripotent stem (iPS) cells that are capable of transdifferentiating into diverse types of somatic cell lines. In this study, we examined if functional cardiomyocytes (CMs) can be produced from mouse cardiac fibroblasts (CFs), using iPS cell factor-based reprogramming. CFs were isolated from Oct4-GFP-C57 mice and infected with a retrovirus expressing the Yamanaka reprogramming factors, Oct4, Sox2, Klf4, and c-Myc to reprogram the CFs into a CF-iPS cell line. Primary mouse embryonic fibroblast cells (MEFs) were used as a control. We found that the dedifferentiated CF-iPS cells showed similar biological characteristics (morphology, pluripotent factor expression, and methylation level) as embryonic stem cells (ESs) and MEF-iPS cells. We used the classical embryoid bodies (EBs)-based method and a transwell CM co-culture system to simulate the myocardial paracrine microenvironment for performing CF-iPS cell cardiogenic differentiation. Under this simulated myocardial microenvironment, CF-iPS cells formed spontaneously beating EBs. The transdifferentiated self-beating cells expressed cardiac-specific transcription and structural factors and also displayed typical myocardial morphology and electrophysiological characteristics. CFs can be dedifferentiated into iPS cells and further transdifferentiated into CMs. CFs hold great promise for CM regeneration as an autologous cell source for functional CM in situ without the need for exogenous cell transplantation in ischemic heart disease.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....